Ignite Creation Date:
2024-05-06 @ 2:27 AM
Last Modification Date:
2024-10-26 @ 11:18 AM
Study NCT ID:
NCT02042573
Status:
TERMINATED
Last Update Posted:
2024-02-21
First Post:
2014-01-17
Brief Title:
Preliminary Study to Investigate the Effect of rTMS and SSRI Antidepressants on Leukocyte Expression of the C-FOS and DUSP1 Genes in Patients Treated for Depression
Sponsor:
Centre Hospitalier Universitaire Dijon
Organization:
Centre Hospitalier Universitaire Dijon
Study Overview
Official Title:
TMSFOS Preliminary Study to Investigate the Effect of rTMS and SSRI Antidepressants on Leukocyte Expression of the C-FOS and DUSP1 Genes in Patients Treated for Depression
Status:
TERMINATED
Status Verified Date:
2024-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
The study population is no longer accessible to the investigating team
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
TMSFOS
Brief Summary:
Low frequency rTMS repetitive Transcranial Magnetic Stimulation for the treatment of patients with depression is responsible for a decrease in the expression of the C-FOS and DUSP1 genes in peripheral blood leukocytes The decrease in C-FOS expression could be explained by the inhibiting effect of low-frequency rTMS in contrast high-frequency rTMS causes activation of the cerebral cortex Rossi 2009 This genetic effect could correlate with the antidepressant effect Hausmann 2000
According to this hypothesis the genetic effect related to medical antidepressant treatments deserves to be studied because we could observe
either a decrease in the expression of the C-FOS and DUSP1 genes related to the antidepressant effect of the medical antidepressant treatment
or an increase in the expression of the C-FOS and DUSP1 genes related to cerebral activation due to the medical antidepressant treatment
In summary we wish to determine the validity of this hypothesis by comparing the genetic effect of rTMS with that of medical antidepressants to know if
this genetic effect is specific to rTMS or common rTMS and medical antidepressants
this effect correlates with the clinical improvement induced by rTMS and by medical antidepressants
this early modification in the C-FOS and DUSP1 genes may be predictor of the therapeutic response to rTMS and antidepressants early decrease in gene expression
the absence of any decrease or increase in C-FOS and or DUSP1 expression is a predictor of therapeutic resistance to rTMS andor medical antidepressants
According to this hypothesis the genetic effect related to medical antidepressant treatments deserves to be studied because we could observe
either a decrease in the expression of the C-FOS and DUSP1 genes related to the antidepressant effect of the medical antidepressant treatment
or an increase in the expression of the C-FOS and DUSP1 genes related to cerebral activation due to the medical antidepressant treatment
In summary we wish to determine the validity of this hypothesis by comparing the genetic effect of rTMS with that of medical antidepressants to know if
this genetic effect is specific to rTMS or common rTMS and medical antidepressants
this effect correlates with the clinical improvement induced by rTMS and by medical antidepressants
this early modification in the C-FOS and DUSP1 genes may be predictor of the therapeutic response to rTMS and antidepressants early decrease in gene expression
the absence of any decrease or increase in C-FOS and or DUSP1 expression is a predictor of therapeutic resistance to rTMS andor medical antidepressants
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None